FibroBiologics, Charles River Laboratories Team Up to Make Fibroblast-Based Treatments for Chronic Diseases

MT Newswires Live10-18

FibroBiologics (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial expected to start next year.

FibroBiologics is assessing the potential treatment of chronic diseases using fibroblasts, the companies said, adding indications being evaluated include: wound healing, multiple sclerosis, degenerative disc disease, psoriasis, thymic involution reversal, as well as cancer.

Charles River will be the contract development and manufacturing organization that will make the drug products for FibroBiologics' upcoming study, the companies said.

Financial details weren't provided.

Price: 3.4500, Change: +0.13, Percent Change: +3.92

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476237627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-18 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476237627","market":"nz","top_or_hot":-1,"title":"FibroBiologics, Charles River Laboratories Team Up to Make Fibroblast-Based Treatments for Chronic Diseases","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial expected to start next year.</p><p>FibroBiologics is assessing the potential treatment of chronic diseases using fibroblasts, the companies said, adding indications being evaluated include: wound healing, multiple sclerosis, degenerative disc disease, psoriasis, thymic involution reversal, as well as cancer.</p><p>Charles River will be the contract development and manufacturing organization that will make the drug products for FibroBiologics' upcoming study, the companies said.</p><p>Financial details weren't provided.</p><p>Price: 3.4500, Change: +0.13, Percent Change: +3.92</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroBiologics, Charles River Laboratories Team Up to Make Fibroblast-Based Treatments for Chronic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroBiologics, Charles River Laboratories Team Up to Make Fibroblast-Based Treatments for Chronic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-18 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FibroBiologics (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TISI","symbol_name":"Team Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476237627","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476237627","pubTimestamp":1729257931,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"FibroBiologics (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial exp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TISI":"Team Inc","BK7095":"多种金属与采矿","CRL":"查尔斯河","FBLG":"FibroBiologics","BK4585":"ETF&股票定投概念","BK4121":"生命科学工具和服务","BK4530":"医药外包概念","BK4588":"碎股","BK4120":"环境与设施服务","BK4139":"生物科技","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","CRL.AU":"Comet Resources Ltd"},"translate_title":"FibroBiologics与Charles River Laboratories合作开发基于成纤维细胞的慢性病治疗方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1,"CRL.AU":1,"FBLG":1,"TISI":1},"content_text":"FibroBiologics (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial expected to start next year.FibroBiologics is assessing the potential treatment of chronic diseases using fibroblasts, the companies said, adding indications being evaluated include: wound healing, multiple sclerosis, degenerative disc disease, psoriasis, thymic involution reversal, as well as cancer.Charles River will be the contract development and manufacturing organization that will make the drug products for FibroBiologics' upcoming study, the companies said.Financial details weren't provided.Price: 3.4500, Change: +0.13, Percent Change: +3.92","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476237627"}